Daniel Hunt Net Worth

Daniel Hunt biography

Daniel W. Hunt J.D. serves as Senior Vice President, Chief Business Officer of the Company. Mr. Hunt has served as our Senior Vice President and Chief Business Officer since December 2017. Prior to joining the Company, Mr. Hunt served as General Counsel and Vice President of Corporate Development at CoMentis, Inc., a biotechnology company, from July 2009 to September 2016. Mr. Hunt was an Associate General Counsel at Genentech, Inc. from 2003 to 2009 and prior to that held senior legal and transactional positions at Abgenix, Inc., Roche Molecular Systems, Inc. and Chiron Corporation. Mr. Hunt received a B.S in Biology from the University of Colorado at Boulder and his J.D. from the Boalt Hall School of Law at the University of California, Berkeley.

What is the salary of Daniel Hunt?

As the Senior Vice President and Chief Business Officer of Corvus Pharmaceuticals Inc, the total compensation of Daniel Hunt at Corvus Pharmaceuticals Inc is $1,554,080. There are no executives at Corvus Pharmaceuticals Inc getting paid more.

How old is Daniel Hunt?

Daniel Hunt is 58, he's been the Senior Vice President and Chief Business Officer of Corvus Pharmaceuticals Inc since 2017. There are 10 older and 7 younger executives at Corvus Pharmaceuticals Inc. The oldest executive at Corvus Pharmaceuticals Inc is Dr. Richard A. Miller M.D., 70, who is the Co-Founder, Pres, CEO & Chairman.

What's Daniel Hunt's mailing address?

Daniel's mailing address filed with the SEC is C/O CORVUS PHARMACEUTICALS, INC., 863 MITTEN ROAD, SUITE 102, BURLINGAME, CA, 94010.

Insiders trading at Corvus Pharmaceuticals Inc

Over the last 9 years, insiders at Corvus Pharmaceuticals Inc have traded over $52,808,904 worth of Corvus Pharmaceuticals Inc stock and bought 11,523,300 units worth $85,214,510 . The most active insiders traders include Holdings A/S Novo, Street Partners Llc Adams, and Capital, Llc Eco R1. On average, Corvus Pharmaceuticals Inc executives and independent directors trade stock every 46 days with the average trade being worth of $1,530,854. The most recent stock trade was executed by William Benton Jones on 6 May 2024, trading 20,000 units of CRVS stock currently worth $34,600.

What does Corvus Pharmaceuticals Inc do?

corvus pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class agents that target the immune system to treat patients with cancer. with accomplished and talented scientists, and top-tier investors, we are well positioned in an exciting new era of immuno-oncology.

Corvus Pharmaceuticals Inc executives and stock owners

Corvus Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Daniel Hunt,
  Senior Vice President, Chief Business Officer
• Mehrdad Mobasher,
  Vice President, Chief Medical Officer
• Richard Miller,
  Chairman of the Board, President, Chief Executive Officer
• Leiv Lea,
  Chief Financial Officer
• Dr. Mehrdad Mobasher M.D., M.P.H.,
  Sr. VP & Chief Medical Officer
• Leiv Lea,
  Chief Financial Officer
• Steve Krognes,
  Independent Director
• Peter Thompson,
  Independent Director
• Elisha Gould,
  Independent Director
• Dr. Richard A. Miller M.D.,
  Co-Founder, Pres, CEO & Chairman
• Scott Morrison,
  Independent Director
• Dr. Peter A. Thompson FACP, M.D.,
  Co-Founder & Independent Director
• Linda Grais,
  Independent Director
• Ian Clark,
  Independent Director
• Edith Mitchell,
  Director
• Erik Verner,
  Vice President of Chemistry Research
• William Jones,
  Senior Vice President of Pharmaceutical Development
• Dr. James T. Rosenbaum M.D.,
  Sr. VP of Research
• Dr. Erik J. Verner Ph.D.,
  Co-Founder
• Stephen Willingham,
  Sr. Scientist
• Alan C. Mendelson Esq.,
  Sec.
• Dr. Long Kwei Ph.D.,
  Sr. VP of Biometrics
• Dr. William Benton Jones,
  Sr. VP of Pharmaceutical Devel.
• Debra Horen SPHR,
  VP of HR
• Street Partners Llc Adams,
  10% owner
• Advisors Llc Orbi Med Capit...,
  
• Jason V Coloma,
  SVP, Chief Business Officer
• Holdings A/S Novo,
  10% owner
• Advisors Llc Orbimed,
  Director
• Terry P Gould,
  
• Joseph J Buggy,
  EVP, Discovery Research
• Advisors Llc Orbi Med Capit...,
  
• Capital, Llc Eco R1,
  10% owner
• Jeffrey Arcara,
  Chief Business Officer